Zarnestra Phase III Data Needed Pre-Approval, Oncology Committee Says

FDA's Oncologic Drugs Advisory Committee votes 7 to 4 against recommending accelerated approval of J&J's tipifarnib. Data from the Phase III trial are necessary to identify the appropriate patient population for the oncologic, members say.